---
title: "JonesTrading Remains a Buy on Context Therapeutics (CNTX)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281799907.md"
description: "JonesTrading analyst Soumit Roy has maintained a Buy rating on Context Therapeutics (CNTX) with a price target of $7.00. Roy, who focuses on the Healthcare sector, has an average return of -7.2% and a 32.22% success rate on his stock recommendations. Additionally, Maxim Group's Jason McCarthy also issued a Buy rating for CNTX, while TipRanks reiterated a Hold rating on April 3."
datetime: "2026-04-06T20:39:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281799907.md)
  - [en](https://longbridge.com/en/news/281799907.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281799907.md)
---

# JonesTrading Remains a Buy on Context Therapeutics (CNTX)

In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Context Therapeutics, with a price target of $7.00.

### Easter Sale - 70% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Roy covers the Healthcare sector, focusing on stocks such as CervoMed, Enliven Therapeutics, and Oric Pharmaceuticals. According to TipRanks, Roy has an average return of \-7.2% and a 32.22% success rate on recommended stocks.

In addition to JonesTrading, Context Therapeutics also received a Buy from Maxim Group’s Jason McCarthy in a report issued on April 2. However, on April 3, TipRanks – xAI reiterated a Hold rating on Context Therapeutics (NASDAQ: CNTX).

### Related Stocks

- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [CNTX.US](https://longbridge.com/en/quote/CNTX.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)

## Related News & Research

- [LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)](https://longbridge.com/en/news/286648286.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 | CNTX Stock News](https://longbridge.com/en/news/286757134.md)
- [Bank of America Securities Reaffirms Their Buy Rating on Inhibikase Therapeutics (IKT)](https://longbridge.com/en/news/286542293.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)